New painkiller cocktail could cut opioid use after hip surgery

NCT ID NCT06565910

Recruiting now Symptom relief Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a long-acting form of the anesthetic bupivacaine, combined with regular bupivacaine, can control pain better than the standard drug ropivacaine after hip replacement. Sixty adults with hip fractures or necrosis will receive one of the two treatments via a nerve block before surgery. Researchers will measure pain levels and opioid use for 72 hours after the operation to see which approach works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal bupivacaine plus bupivacaine
What this could lead to: If it works, this could offer longer-lasting pain relief after hip replacement, reducing the need for opioids.
What could go wrong: This is a small, early-phase trial with only 60 participants. The new drug combination may not prove significantly better than the standard anesthetic, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEMORAL NECK FRACTURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avascular necrosis familial avascular necrosis of femoral head femoral neck fracture hip fracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FEMORAL NECK FRACTURES FEMUR HEAD NECROSIS HIP FRACTURES

Contacts and locations

Locations

Department of Anesthesiology, Tongji Hospital, Tongji Medical College, HUST
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.